RCEL Key Statistics, Chart & Performance
The current stock price of RCEL is 3.9 USD. In the past month the price increased by 19.27%. In the past year, price decreased by -54.91%.
RCEL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RCEL. When comparing the yearly performance of all stocks, RCEL is a bad performer in the overall market: 89.24% of all stocks are doing better.
RCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RCEL. Both the profitability and financial health of RCEL have multiple concerns.
RCEL Financial Highlights
Over the last trailing twelve months RCEL reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 18.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.19% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RCEL Forecast & Estimates
12 analysts have analysed RCEL and the average price target is 7.04 USD. This implies a price increase of 80.46% is expected in the next year compared to the current price of 3.9.
For the next year, analysts expect an EPS growth of 36.98% and a revenue growth 7.12% for RCEL
RCEL Ownership
RCEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About RCEL
Company Profile
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 260 full-time employees. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
Company Info
AVITA MEDICAL INC
28159 Avenue Stanford, Suite 220
Valencia California CALIFORNIA 91355 US
CEO: Michael Perry
Employees: 260
Phone: 16613679170
AVITA MEDICAL INC / RCEL FAQ
What does AVITA MEDICAL INC do?
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 260 full-time employees. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
What is the stock price of AVITA MEDICAL INC today?
The current stock price of RCEL is 3.9 USD. The price increased by 12.72% in the last trading session.
What is the dividend status of AVITA MEDICAL INC?
RCEL does not pay a dividend.
What is the ChartMill rating of AVITA MEDICAL INC stock?
RCEL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of AVITA MEDICAL INC (RCEL) based on its PE ratio?
AVITA MEDICAL INC (RCEL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.81).
What is the market capitalization of RCEL stock?
AVITA MEDICAL INC (RCEL) has a market capitalization of 118.91M USD. This makes RCEL a Micro Cap stock.
Can you provide the short interest for RCEL stock?
The outstanding short interest for AVITA MEDICAL INC (RCEL) is 10.03% of its float.